Pre-clinical studies indicate that myeloperoxidase
(MPO) and eosinophil peroxidase (EPO) are non-toxic, non-irritating, non-genotoxic,
and non-sensitizing in various formulations, including solutions, gels,
and sprays. The unique microbicidal mechanisms of MPO and EPO systems
suggest a high margin of safety to support a wide variety of indications.
MPO resistance induction studies found no resistance development in clinically
important bacterial isolates.
Results of in vitro and in vivo
In vitro studies by Exoxemis show rapid microbicidal activity
of MPO against clinically significant antibiotic-resistant and antibiotic-susceptible
strains of gram-negative and gram-positive bacteria, spores, fungi, and
viruses: Methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant enterococci (VRE), extended spectrum beta-lactamase
producers (ESBL), mucoid strains, and multidrug-resistant organisms.
In vivo studies by Exoxemis have demonstrated microbicidal activity
in support of preventing and treating infectious diseases. In addition
to broad spectrum and rapid cidal activity, MPO and its formulations have
been shown, in early studies, to be both safe and effective.
A comparison of MPO system to antibiotics for
irrigation of implant material
Residual bacteria at the site of implant surgery can lead to acute and
delayed infection. Recent studies conducted by Exoxemis clearly demonstrated
that the MPO enzyme system rapidly and completely kills residual S.
aureus, even in the presence of implant material. Antibiotic solutions
traditionally used in the clinic failed to do so, and in fact, showed
re-growth of the initial inoculum. Future studies are needed to evaluate
the efficacy of the MPO enzyme system against other pathogens and implant
materials, and in preventing contamination, biofilm formation, and subsequent